internatnew

Manufacturing Capabilites

Primary Sites

  • Site-specific centres of production excellence
  • Large-scale capabilities leading to COGS benefits
  • Ensures uniform quality globally
  • Specialist capabilities and skills
  • Provide overall strategic advantage for Group
  • Globally accredited
primary2

SOUTH AFRICA: One of our flagship manufacturing sites in Port Elizabeth, South Africa

API Facilities

  • Biological capabilities including heparin where Aspen has become a significant global player
  • Capabilities include biochemicals, peptides, steroid/hormones, high potency products and other chemicals
  • Manufacturing capabilities enable control and access over niche pipeline opportunites
  • Provides vertical integration advantage for Group
api2

FRANCE: Our Notre Dame de Bondeville specialist sterile manufacturing site in Rouen, France

Regional Facilities

  • Supply local/regional needs across diverse territories
regional1

FDF Capacity & Capability

FY 2000

Tablets only

manu-graph1

FY 2013

Predominantly solids with some Speciality

manu-graph2

FY 2017

Dominant sterile platform with Speciality & Solids

manu-graph3

FY 2022

Further evolution to Sterile Manufacturing

manu-graph4

API Capacity & Capability

Total Capacity 200 KvH

Capabilites
Anaesthetics
Muscle relaxants
Narcotics
Analgesics
Antineoplastics
Bronchodilators

FY 2013

manu-graph5

FY 2017

manu-graph6

Total Capacity 200 KvH

Added Capabilites
High Potency & Cytotoxics
Steroids/Alkaloids/Heterocyclics
Conugated & Esterified estrogens
Peptides
Hormonal & General intermediates
Biochemicals - Heparin & Danaparoid Gonadotrpins

NDB:

  • Purification of Fondaparinux
  • Conversion of heparin to Nadroparin
  • Broader geographic diversity
  • Enhanced capabilities
  • Five fold capacity increase